Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bioequivalence Study of Cagrilintide B + Placebo Semaglutide I and Cagrilintide D Once Weekly in Participants With Overweight or Obesity

NCT07597018 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07597018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07597018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bioequivalence Study of Cagrilintide B + Placebo Semaglutide I and Cagrilintide D Once Weekly in Participants With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Recruiting
Start date
May 18, 2026
Completion date
June 1, 2027
Enrollment
234 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight